Elysium, founded by Leonard Guarente, is on a mission is to translate critical scientific advancements in aging research into accessible health products and technologies. The current pipeline includes preclinical and clinical trials for skin, microbiome, muscle, cognition, UV damage, menopausal syndromes, and circadian rhythm. At present Elysium markets four products: Basis, Matter, Format, Signal, and Index. Although these products are categorized as supplements rather than pharmaceuticals, Elysium is setting up clinical trials to establish thieir safety and effectiveness. As of May 2023 Elysium has 18 clinical trials listed on clinicaltrials.gov.. This foundation allows Elysium to establish an approach to scientific discovery and customer support that enables the pursuit of lifelong health and wellness. Successful skeletal muscle regeneration depends on a functional pool of muscle stem cells, termed satellite cells (SC). SC are in a quiescent state throughout adulthood, but undergo multiple cycles of proliferation and self-renewal in response to muscle damage. During aging, there is a loss of SC quiescence, and SC more readily enter an ageing-state impairing their function. Animal studies have revealed a common denominator for increasing SC function and activity, namely Sirtuin activation. Natural stimulators of Sirtuins includes Nicotinamide Riboside (NR) (a Nicotinamide adenine dinucleotide (NAD+) precursor) and the polyphenol Pterostilbene (PT). In this study, the aim was to investigate if NR+PT supplementation will promote skeletal muscle regeneration after muscle damage in elderly humans by enhanced recruitment of SC. The study was completed in September 2020. No results were announced but a 2022 study, which was very similar found no benefit to patients given NR and PT(https://pubmed.ncbi.nlm.nih.gov/35998039/) ClinicalTrials.gov Identifier: NCT03754842
×
